Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Switching between cyclosporin formulations. What are the risks?

A J Olyaei1, A M deMattos, W M Bennett

  • 1Division of Nephrology, Hypertension and Clinical Pharmacology, Oregon Health Sciences University, Portland, USA.

Drug Safety
|June 1, 1997
PubMed
Summary

Switching cyclosporin formulations may cause adverse effects and rejection in renal transplant patients. More research is needed to confirm therapeutic equivalency and long-term safety of different cyclosporin preparations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Cell Carcinoma in Renal Transplantation: The Case for Surveillance.

Transplantation proceedings·2017
Same author

Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report.

Transplantation proceedings·2015
Same author

Enteric oxalate nephropathy in the renal allograft: an underrecognized complication of bariatric surgery.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Use of organs for transplantation from a donor with primary meningoencephalitis due to Naegleria fowleri.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008
Same author

Increased vascular resistance and not salt retention characterizes cyclosporine A-induced hypertension: report in an anuric patient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
Same author

Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors.

Kidney international·2006

Area of Science:

  • Immunology
  • Pharmacology
  • Nephrology

Background:

  • Cyclosporin has improved transplant survival through immunosuppression.
  • Cyclosporin is a potent immunosuppressant with a narrow therapeutic window.
  • Different cyclosporin formulations exist, raising concerns about therapeutic equivalency.

Observation:

  • Recent reports suggest adverse reactions and rejection upon switching cyclosporin formulations.
  • Uncertainty exists regarding the therapeutic equivalency of different cyclosporin formulations.
  • Pharmacokinetic and pharmacodynamic monitoring is crucial during formulation changes.

Findings:

  • Switching between cyclosporin formulations may induce toxicity and acute cellular rejection.
  • Limited data exist on the long-term effects of microemulsion formulation's high peak concentrations.

Related Experiment Videos

  • The impact of reduced pharmacokinetic variability on graft and patient survival is unclear.

    • Implications:

    • Caution is advised when switching cyclosporin formulations in renal transplant recipients.
    • Long-term studies are necessary to assess cyclosporin-induced chronic nephropathy risks.
    • Further research is needed to clarify the clinical significance of microemulsion formulation benefits.